C4 Therapeutics, Inc. (CCCC)
| Market Cap | 399.96M +256.5% |
| Revenue (ttm) | 34.86M -12.4% |
| Net Income | -103.80M |
| EPS | -1.08 |
| Shares Out | 110.18M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,821,362 |
| Open | 3.690 |
| Previous Close | 3.680 |
| Day's Range | 3.475 - 3.785 |
| 52-Week Range | 1.210 - 3.950 |
| Beta | 2.78 |
| Analysts | Strong Buy |
| Price Target | 12.20 (+236.09%) |
| Earnings Date | May 12, 2026 |
About CCCC
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutat... [Read more]
Financial Performance
In 2025, C4 Therapeutics's revenue was $35.95 million, an increase of 1.02% compared to the previous year's $35.58 million. Losses were -$104.99 million, -0.31% less than in 2024.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for CCCC stock is "Strong Buy." The 12-month stock price target is $12.2, which is an increase of 236.09% from the latest price.
News
C4 Therapeutics reports Q1 EPS (20c), consensus (26c)
Reports Q1 revenue $6.15M, consensus $4.42M. “During the first quarter, we made strong progress advancing cemsidomide as a potential best-in-class IKZF1/3 degrader for the treatment of multiple myelom...
C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) scie...
C4 Therapeutics, Roche expand partnership with new cancer deal worth over $1 billion
C4 Therapeutics said on Thursday it has entered into a deal focused on research and development of a type of cancer drug with Swiss drugmaker Roche that could be worth more than $1 billion.
C4 Therapeutics expands long-term partnership with Roche
C4 Therapeutics (CCCC) announced that it has entered into a new collaboration agreement with Roche (RHHBY) to advance research in the emerging degrader-antibody conjugate modality. Working together, C...
C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)
Agreement Focused on Developing DACs With Payloads For Two Oncology Targets, With an Option for a Third Target C4T to Develop Degraders With Payload Properties; Roche to Conjugate Payloads to Targeted...
C4 Therapeutics doses first patient in cemsidomide trial
C4 Therapeutics (CCCC) announced that the first patient has been dosed with cemsidomide, an oral IKZF1/3 degrader, in a Phase 1b trial evaluating cemsidomide and dexamethasone in combination with elra...
C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma
Novel Combination Regimen Positions Cemsidomide for Use in Earlier Lines of Therapy Novel Combination Regimen Positions Cemsidomide for Use in Earlier Lines of Therapy
C4 Therapeutics Transcript: Barclays 28th Annual Global Healthcare Conference
Cemsidomide is advancing in global Phase 2 and upcoming Phase 1B studies for multiple myeloma, showing strong efficacy and safety in heavily pretreated patients. The company’s robust pipeline, strategic partnerships, and financial runway support key milestones through 2028.
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WATERTOWN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science,...
C4 Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
The session highlighted a robust clinical and discovery pipeline, with cemsidomide positioned as a best-in-class IKZF1/3 degrader for myeloma. Key milestones include ongoing phase II and upcoming combination studies, a focus on regulatory rigor, and a strong safety-efficacy balance supporting accelerated approval prospects.
C4 Therapeutics price target raised to $7 from $5 at Barclays
Barclays raised the firm’s price target on C4 Therapeutics (CCCC) to $7 from $5 and keeps an Overweight rating on the shares. The firm says the company’s execution continues. Published…
C4 Therapeutics reports Q4 EPS (18c), consensus (34c)
Reports Q4 revenue $11.016M, consensus $4.48M. “We made significant progress in 2025, notably demonstrating cemsidomide’s best-in-class potential, establishing an efficient and differentiated regulato...
C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Cemsidomide Advancing into Later-stage Development with Potential for Accelerated Approval; First Patient Dosed in the Phase 2 MOMENTUM Trial for Multiple Myeloma in the Fourth Line or Later Phase 1b ...
C4 Therapeutics price target raised to $30 from $20 at Brookline
Brookline raised the firm’s price target on C4 Therapeutics (CCCC) to $30 from $20 and keeps a Buy rating on the shares. The timing of the Phase II cemsidomide/CFT6455 MOMENTUM…
C4 Therapeutics to Participate in Upcoming March Conferences
WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) sci...
C4 Therapeutics announces first patient dosed in Phase 2 MOMENTUM trial
C4 Therapeutics (CCCC) announced that the first patient has been dosed in the Phase 2 MOMENTUM trial evaluating cemsidomide in combination with dexamethasone for the treatment of relapsed/refractory m...
C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma
Enrollment for Phase 2 MOMENTUM Trial Expected to Be Completed in Q1 2027 Phase 1b Trial of Cemsidomide in Combination with Elranatamab on Track to Initiate in Q2 2026 WATERTOWN, Mass., Feb. 23, 2026...
C4 Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Cemsidomide is advancing to phase II and IB trials in myeloma, with MRD negativity as a key regulatory endpoint. Financing extends runway to 2028, supporting both single-agent and combination studies, while collaborations and a diversified pipeline underpin long-term strategy.
C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
WATERTOWN, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) sci...
C4 Therapeutics outlines milestones through 2028
C4 Therapeutics (CCCC) outlined milestones through 2028 and highlighted recent achievements. Anticipated Key Strategic Milestones: Cemsidomide – In Q1 2026, initiate the Phase 2 MOMENTUM trial of cems...
C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways
Cemsidomide Phase 2 MOMENTUM Trial On Track to Initiate in Q1 2026; Recommended Phase 2 Dose is 100 µg Cemsidomide Phase 1b Trial in Combination With Elranatamab On Track to Initiate in Q2 2026 Intern...
C4 Therapeutics price target lowered to $5 from $10 at Barclays
Barclays lowered the firm’s price target on C4 Therapeutics (CCCC) to $5 from $10 and keeps an Overweight rating on the shares. The firm adjusted price targets in the biotechnology…
C4 Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference
Two clinical programs are advancing, with cemsidomide showing strong efficacy and safety in a highly refractory population and moving to phase two. Financial runway extends through 2028, with key data readouts and potential milestone payments expected. Combination studies and global expansion are underway.
C4 Therapeutics initiated with a Buy at TD Cowen
TD Cowen initiated coverage of C4 Therapeutics (CCCC) with a Buy rating and no price target C4 is one of the few companies with clinical validation across molecular glues and…
C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
WATERTOWN, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, ...